Genomic alterations in neuroendocrine cancers of the ovary

George Yaghmour, Philippe Prouet, Eric Wiedower, Omer Hassan Jamy, Rebecca Feldman, Jason C. Chandler, Manjari Pandey, Michael Martin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: As we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods: Patients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007-2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results: Forty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12-75] and 26 years [range 8-40], respectively) than patients with NET-O 62 [range 13-76] or SCLC 66 [range 36-86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified. Conclusions: No recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.

Original languageEnglish (US)
Article number52
JournalJournal of Ovarian Research
Volume9
Issue number1
DOIs
StatePublished - Aug 26 2016

Fingerprint

Ovarian Neoplasms
Ovary
Small Cell Carcinoma
Neuroendocrine Tumors
Small Cell Lung Carcinoma
Mutation
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Yaghmour, G., Prouet, P., Wiedower, E., Jamy, O. H., Feldman, R., Chandler, J. C., ... Martin, M. (2016). Genomic alterations in neuroendocrine cancers of the ovary. Journal of Ovarian Research, 9(1), [52]. https://doi.org/10.1186/s13048-016-0259-2

Genomic alterations in neuroendocrine cancers of the ovary. / Yaghmour, George; Prouet, Philippe; Wiedower, Eric; Jamy, Omer Hassan; Feldman, Rebecca; Chandler, Jason C.; Pandey, Manjari; Martin, Michael.

In: Journal of Ovarian Research, Vol. 9, No. 1, 52, 26.08.2016.

Research output: Contribution to journalArticle

Yaghmour, G, Prouet, P, Wiedower, E, Jamy, OH, Feldman, R, Chandler, JC, Pandey, M & Martin, M 2016, 'Genomic alterations in neuroendocrine cancers of the ovary', Journal of Ovarian Research, vol. 9, no. 1, 52. https://doi.org/10.1186/s13048-016-0259-2
Yaghmour G, Prouet P, Wiedower E, Jamy OH, Feldman R, Chandler JC et al. Genomic alterations in neuroendocrine cancers of the ovary. Journal of Ovarian Research. 2016 Aug 26;9(1). 52. https://doi.org/10.1186/s13048-016-0259-2
Yaghmour, George ; Prouet, Philippe ; Wiedower, Eric ; Jamy, Omer Hassan ; Feldman, Rebecca ; Chandler, Jason C. ; Pandey, Manjari ; Martin, Michael. / Genomic alterations in neuroendocrine cancers of the ovary. In: Journal of Ovarian Research. 2016 ; Vol. 9, No. 1.
@article{2d52ea7120a9477a96879c2fc01a49b0,
title = "Genomic alterations in neuroendocrine cancers of the ovary",
abstract = "Background: As we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods: Patients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007-2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results: Forty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12-75] and 26 years [range 8-40], respectively) than patients with NET-O 62 [range 13-76] or SCLC 66 [range 36-86]. SCCO patients were more likely to be metastatic (70 {\%}) than SCCO-HT (50 {\%}) or NET-O (33 {\%}) patients, but at a similar rate to SCLC patients (65 {\%}). PD1 expression varied across tumor type with SCCO (100 {\%}), SCCO-HT (60 {\%}), NET-O (33 {\%}) vs SCLC (42 {\%}). PDL1 expression also varied with SCCO (50 {\%}), SCCO-HT (20 {\%}), NET-O (33 {\%}) and SCLC (0 {\%}). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified. Conclusions: No recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.",
author = "George Yaghmour and Philippe Prouet and Eric Wiedower and Jamy, {Omer Hassan} and Rebecca Feldman and Chandler, {Jason C.} and Manjari Pandey and Michael Martin",
year = "2016",
month = "8",
day = "26",
doi = "10.1186/s13048-016-0259-2",
language = "English (US)",
volume = "9",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Genomic alterations in neuroendocrine cancers of the ovary

AU - Yaghmour, George

AU - Prouet, Philippe

AU - Wiedower, Eric

AU - Jamy, Omer Hassan

AU - Feldman, Rebecca

AU - Chandler, Jason C.

AU - Pandey, Manjari

AU - Martin, Michael

PY - 2016/8/26

Y1 - 2016/8/26

N2 - Background: As we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods: Patients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007-2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results: Forty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12-75] and 26 years [range 8-40], respectively) than patients with NET-O 62 [range 13-76] or SCLC 66 [range 36-86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified. Conclusions: No recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.

AB - Background: As we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO. Methods: Patients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007-2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes. Results: Forty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12-75] and 26 years [range 8-40], respectively) than patients with NET-O 62 [range 13-76] or SCLC 66 [range 36-86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified. Conclusions: No recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.

UR - http://www.scopus.com/inward/record.url?scp=84984604156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984604156&partnerID=8YFLogxK

U2 - 10.1186/s13048-016-0259-2

DO - 10.1186/s13048-016-0259-2

M3 - Article

VL - 9

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 52

ER -